Tag: TLX
Telix Pharmaceuticals to begin phase two prostate cancer imaging study
Biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has been given the green light to commence a phase two study involving its medical imaging technology on...
Telix Pharmaceuticals partners with Mexican nuclear science firm to advance prostate imaging technology
Australian biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has completed an in-licensing agremeent with Mexico’s Instituto Nacional de Investigaciones Nucleares (ININ) for a clinical-stage radiopharmaceutical...
Telix Pharmaceuticals acquires Belgium-based Advanced Nuclear Medicine Ingredients
Telix Pharmaceuticals (ASX: TLX) has made a play for Belgium company Advanced Nuclear Medicine Ingredients, with the takeover valuing ANMI at over £5.15 million...
Telix Pharmaceuticals readies recruitment for phase 3 trial in renal cancer
Melbourne-based biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) is preparing to commence recruitment for its zirconium imaging in renal cancer oncology (ZIRCON) phase 3 trial...
Telix Pharmaceuticals strikes cancer treatment access deal with GenesisCare
Biopharmaceutical company Telix Pharmaceuticals (ASX: TLX) has teamed up with the largest private provider of oncology services in Australia and Europe, GenesisCare, to accelerate...